BioNTech Results Presentation Deck
BNT113: Unmet medical need for HPV-Associated
need for HPV-Associated
ASIR
●
0 to <1
1 to <5
15 to <10
≥10
No data
NA
HPV+ Cancer is a Growing
Global Public Health Concern
Worldwide HPV-attributable cases (2018) = 690,000
(de Martel et al. 2020, Lancet Glob Health)
• Several types: HNSCC, Cervical, Anal, Vulvar, Vaginal,
Penile
HNSCC is the sixth most common cancer worldwide,
with 890,000 new cases and 450,000 deaths in 20182
Oropharyngeal is most common HNSCC, accounting
for 70% of cases, and 80-90% are HPV 16+³
Limited treatment options for patients not responding to
or relapse on CPI¹
• HPV16+ HNSCC typically occur in younger people and is
not associated with tobacco or alcohol use
●
HNSCC
HNSCC
>60% of patients diagnosed with late-stage HNSCC
Current treatment options carry significant treatment
burden or only work for some patients 4:
Chemotherapy, surgery, radiation
●
●
CPI
Current SOC for
recurrent/metastatic HNSCC
pembrolizumab5
nivolumab6
chemotherapy
HPV, human papilloma virus; HNSCC, head and neck squamous cell carcinoma, CPI, check point inhibitor; R/R refractory/recurrent
¹Sabatini ME and Chiocca S. BJC 2020; 122:306-314, 2Johnson DE, et al., 2020, Nature Reviews Disease Primers 6:92
26 Saraiya et al. 2015, Vaccines; 4HNSCC NCCN Guidelines 2020, HNSCC ESMO Guidelines 2020; 5Burtness, et al. Lancet 2019 Nov 23; 394 (10212):1915-28;
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563923/pdf/nihms-1024161.pdf
ORR
17%
13.3%
5.8%
MOS
(months)
13.6
7.7
5.1
mPFS (months)
8.0
2.0
2.3
BIONTECHView entire presentation